# GSK plc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/GSK plc). ## Overview GSK plc is a global biopharma company that develops and commercializes prescription medicines, vaccines, and specialty treatments. Its business is organized around research, development, manufacturing, and global distribution across major markets, with a material presence in the United Kingdom, the United States, and other international regions. ## Products & services • Vaccines for infectious disease prevention • Specialty medicines for HIV and other chronic conditions • Respiratory and immunology medicines • Oncology and other specialty treatments • Research, development, and commercialization of biopharma assets - **Vaccines** (26%) — Preventive vaccines sold to public health systems, governments, and private providers. - **Specialty Medicines** (44%) — Prescription medicines for infectious diseases, HIV, respiratory, immunology, and oncology. - **General Medicines** (18%) — Established medicines and branded treatments used in primary care and select specialist settings. - **R&D and Pipeline Assets** (12%) — Development-stage products and acquired assets that may not yet generate commercial revenue. - Vaccines for infectious disease prevention - Specialty medicines for HIV and other chronic conditions - Respiratory and immunology medicines - Oncology and other specialty treatments - Research, development, and commercialization of biopharma assets ## Customers GSK sells primarily to healthcare systems, hospitals, clinics, pharmacies, and government buyers that procure medicines and vaccines for patient treatment and public immunization programs. It also serves specialist physicians and managed-care channels that influence prescribing and reimbursement for complex therapies. In the U.S., commercial and government reimbursement arrangements are especially important because rebates and chargebacks affect realized net sales. - **Government and public health buyers** (primary) — Buy vaccines and essential medicines for national immunization and treatment programs. - **Healthcare providers** (primary) — Hospitals, clinics, and specialist centers that administer prescription therapies. - **Pharmacies and distributors** (secondary) — Purchase branded medicines for downstream dispensing to patients. - **Payers and reimbursement channels** (primary) — Influence realized sales through rebates, chargebacks, and access decisions. - **Specialist prescribers** (secondary) — Physicians who drive use of HIV, respiratory, immunology, and oncology products. - National health systems buying vaccines and essential medicines - Hospitals and clinics treating infectious, respiratory, and oncology patients - Specialist physicians prescribing HIV and other specialty therapies - Pharmacies and distributors that channel branded prescription drugs - Government and reimbursed buyers that require rebates and chargebacks ## Geography GSK is a multinational business with sales, R&D, and commercial operations across North America, Europe, and other international markets. The company has a particularly important U.S. footprint, while the UK remains central as its corporate base and operating hub. Geography matters because reimbursement, pricing, and regulatory frameworks differ significantly by country and affect both demand access and net realized revenue. - United States is a core market for specialty medicines and reimbursement exposure - United Kingdom is the corporate and operating base - Europe contributes through vaccines and prescription medicines - International markets diversify demand and regulatory exposure - Local reimbursement rules affect net sales and product access ## Strategy GSK's strategy centers on using science, technology, and internal R&D to build a pipeline of differentiated medicines and vaccines. It also relies on acquisitions and asset development to expand specialty medicine capabilities and deepen long-term commercial opportunities. Maintaining access to major reimbursement systems and progressing assets through regulatory approval are central to its competitive position. - **Progress pipeline assets toward approval** (short-term) — Approved products are the main route to future commercial revenue and scale. - **Expand specialty medicine franchises** (medium-term) — Specialty therapies can create durable demand in complex chronic diseases. - **Strengthen vaccines and prevention** (medium-term) — Vaccines provide large-scale public health relevance and diversified demand. - Advance pipeline assets through clinical and regulatory milestones - Strengthen specialty medicines across infectious disease, HIV, and oncology - Invest in vaccines and prevention-focused healthcare products - Integrate acquired assets into the commercial and R&D engine - Protect market access in reimbursed healthcare systems ## Risks GSK faces the usual pharmaceutical risks around clinical trial failure, regulatory delays, and competition from alternative therapies. Its U.S. business is also exposed to rebate, chargeback, and return-related gross-to-net deductions, which can move reported revenue materially from period to period. Acquired development assets add execution risk because they may remain loss-making until approval and commercial launch. - **Pipeline and regulatory risk** [high] — Drug candidates only generate value if trials succeed and approvals are obtained. - **Gross-to-net revenue volatility in the U.S.** [high] — Rebates, chargebacks, and returns reduce recognized revenue and are judgmental estimates. - **Integration and commercialization risk for acquired assets** [medium] — Development-stage assets may take time to integrate and monetize after acquisition. - **Competition and pricing pressure** [high] — Large pharma markets are crowded and access decisions can constrain uptake. - Clinical and regulatory failure can stop pipeline assets before commercialization - U.S. rebates, chargebacks, and returns can materially change reported net sales - Competition from other biopharma companies can pressure market share and pricing - Acquired assets may stay loss-making until approval and launch - Goodwill and intangible assets may face future impairment risk ## Accounting GSK's reported revenue is heavily influenced by gross-to-net deductions, especially U.S. rebates, chargebacks, and returns, which require estimation at each reporting date. Acquired intangible assets and goodwill are also important because they can materially affect the balance sheet and future impairment testing. Development-stage acquisitions may produce no revenue until approval, while the fair value allocation for recent acquisitions remains provisional until final purchase accounting is completed. - **Revenue deductions and RAR accruals** — Affects top-line comparability and gross-to-net margins - **Goodwill and intangible assets** — Can lead to non-cash write-downs if asset values weaken - **Provisional acquisition accounting** — Can alter the balance sheet and future amortization - **Development-stage asset capitalization** — Affects earnings timing and R&D-related asset recognition - Gross-to-net deductions affect recognized revenue through rebates and returns - RAR accruals are a significant estimation area for U.S. pharmaceutical sales - Acquired intangibles and goodwill require future impairment assessment - Provisional purchase accounting can change asset values after acquisition - Development assets may remain loss-making before approval and launch --- *Last updated: 2026-09-28T12:03:46.125241+00:00*